Bayer Ordered to Pay $2.1 Billion in Roundup Cancer Case

Bayer Ordered to Pay $2.1 Billion in Roundup Cancer Case

1 minute read
Updated 2 days ago

Jury Verdict and Bayer's Response

A Georgia jury has mandated , the parent company of , to pay nearly $2.1 billion to , who claims Roundup caused his non-Hodgkin's lymphoma, marking a significant legal victory for plaintiffs in Roundup-related cases.

Bayer intends to appeal the verdict, maintaining that Roundup is safe based on scientific evidence and regulatory consensus, and has previously set aside $16 billion for settlements amid over 177,000 lawsuits.

Legal and Scientific Controversies

The case highlights ongoing disputes over glyphosate, Roundup's key ingredient, with some studies linking it to cancer, though the EPA categorizes it as unlikely carcinogenic when used as directed.

Critics argue Bayer has ignored scientific studies on Roundup's toxicity, while the company and its supporters lobby for legal protections against such claims, citing unsustainable litigation costs and potential impacts on Roundup's availability.
This is a beta feature. We cannot guarantee the accuracy or quality of responses.